Skip to main content
SpringerLink
Log in

Management of Atrial Fibrillation in the Outpatient Setting

  • Chapter
  • First Online:
Handbook of Outpatient Cardiology

  • 1234 Accesses

Abstract

Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia. It can be precipitated by multiple physiologic stressors and electrolyte abnormalities in patient with both structurally normal and abnormal hearts and can result in patient discomfort, hemodynamic instability, heart failure, and thromboembolism. Prevention of stroke with risk-based application of systemic anticoagulation is the most important treatment goal, and numerous pharmacologic and procedure-based therapies are available for the control of ventricular rate and atrial rhythm.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 119.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 159.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Abbreviations

AF:

Atrial fibrillation

AV:

Atrioventricular

CTI:

Cavo-tricuspid isthmus

DAPT:

Dual antiplatelet therapy

DCCV:

Direct current cardioversion

DOAC:

Direct oral anticoagulant

INR:

International normalized ratio

LAA:

Left atrial appendage

LV:

Left ventricle

OAC:

Oral anticoagulation

OSA:

Obstructive sleep apnea

TEE:

Transesophageal echocardiogram

References

  1. Chugh SS, Havmoeller R, Narayanan K, Singh D, Rienstra M, Benjamin EJ, et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation. 2014;129(8):837–47.

    Article  Google Scholar 

  2. Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001;285(18):2370–5.

    Article  CAS  Google Scholar 

  3. Zimetbaum PJ, Buxton AE, Josephson ME. Practical clinical electrophysiology. Lippincott Williams & Wilkins; 2018. p. 67–89.

    Google Scholar 

  4. Martínez-González MÁ, Toledo E, Arós F, Fiol M, Corella D, Salas-Salvadó J, et al. Extravirgin olive oil consumption reduces risk of atrial fibrillation: the PREDIMED (Prevención con Dieta Mediterránea) trial. Circulation. 2014;130(1):18–26.

    Article  Google Scholar 

  5. Voskoboinik A, Kalman JM, De Silva A, Nicholls T, Costello B, Nanayakkara S, et al. Alcohol abstinence in drinkers with atrial fibrillation. N Engl J Med. 2020;382(1):20–8.

    Article  Google Scholar 

  6. Soliman EZ, Rahman AF, Zhang Z-M, Rodriguez CJ, Chang TI, Bates JT, et al. Effect of intensive blood pressure lowering on the risk of atrial fibrillation. Hypertension. 2020;75(6):1491–6.

    Article  CAS  Google Scholar 

  7. Israel CW, Gronefeld G, Ehrlich JR, Li YG, Hohnloser SH. Long-term risk of recurrent atrial fibrillation as documented by an implantable monitoring device. Implications for optimal patient care [Internet]. ACC Curr J Rev. 2004;13:49–50. Available from: https://doi.org/10.1016/j.accreview.2004.03.016.

  8. Tayal AH, Tian M, Kelly KM, Jones SC, Wright DG, Singh D, et al. Atrial fibrillation detected by mobile cardiac outpatient telemetry in cryptogenic TIA or stroke. Neurology. 2008;71(21):1696–701.

    Article  CAS  Google Scholar 

  9. Diederichsen SZ, Haugan KJ, Kronborg C, Graff C, Højberg S, Køber L, et al. Comprehensive evaluation of rhythm monitoring strategies in screening for atrial fibrillation. [Internet]. Circulation. 2020;141:1510–22. Available from: https://doi.org/10.1161/circulationaha.119.044407.

  10. Perez MV, Mahaffey KW, Hedlin H, Rumsfeld JS, Garcia A, Ferris T, et al. Large-scale assessment of a smartwatch to identify atrial fibrillation. N Engl J Med. 2019;381(20):1909–17.

    Article  Google Scholar 

  11. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med. 2009;360(20):2066–78.

    Google Scholar 

  12. January CT, Wann LS, Calkins H, Chen LY, Cigarroa JE, Cleveland JC Jr, et al. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration With the Society of Thoracic Surgeons. Circulation. 2019;140(2):e125–51.

    Article  Google Scholar 

  13. Connolly SJ, Pogue J, Eikelboom J, Flaker G, Commerford P, Franzosi MG, et al. Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. Circulation. 2008;118(20):2029–37.

    Article  CAS  Google Scholar 

  14. Douketis JD, Spyropoulos AC, Duncan J, Carrier M, Le Gal G, Tafur AJ, et al. Perioperative management of patients with atrial fibrillation receiving a direct oral anticoagulant. JAMA Intern Med [Internet]. 2019.; Available from: https://doi.org/10.1001/jamainternmed.2019.2431

  15. Gibson CM, Mehran R, Bode C, Halperin J, Verheugt F, Wildgoose P, et al. An open-label, randomized, controlled, multicenter study exploring two treatment strategies of rivaroxaban and a dose-adjusted oral vitamin K antagonist treatment strategy in subjects with atrial fibrillation who undergo percutaneous coronary intervention (PIONEER AF-PCI). Am Heart J. 2015;169(4):472–8.

    Article  CAS  Google Scholar 

  16. Lopes RD, Heizer G, Aronson R, Vora AN, Massaro T, Mehran R, et al. Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation. N Engl J Med. 2019;380(16):1509–24.

    Article  CAS  Google Scholar 

  17. Van Gelder IC, Groenveld HF, Crijns HJGM, Tuininga YS, Tijssen JGP, Alings AM, et al. Lenient versus strict rate control in patients with atrial fibrillation. N Engl J Med. 2010;362(15):1363–73.

    Article  Google Scholar 

  18. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med. 2002;347(23):1825–33.

    Google Scholar 

  19. Kirchhof P, Camm AJ, Goette A, Brandes A, Eckardt L, Elvan A, et al. Early rhythm-control therapy in patients with atrial fibrillation. N Engl J Med. 2020;383(14):1305–16.

    Article  Google Scholar 

  20. Pluymaekers NAHA, Dudink EAMP, Luermans JGLM, Meeder JG, Lenderink T, Widdershoven J, et al. Early or delayed cardioversion in recent-onset atrial fibrillation. N Engl J Med. 2019;380(16):1499–508.

    Article  Google Scholar 

  21. Abu-El-Haija B, Giudici MC. Predictors of long-term maintenance of normal sinus rhythm after successful electrical cardioversion. Clin Cardiol. 2014;37(6):381–5.

    Article  Google Scholar 

  22. Friberg L, Rosenqvist M, Lip GYH. Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study. Eur Heart J. 2012;33(12):1500–10.

    Article  Google Scholar 

  23. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139–51.

    Article  CAS  Google Scholar 

  24. Granger CB, Alexander JH, McMurray JJV, Lopes RD, Hylek EM, Hanna M, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981–92.

    Article  CAS  Google Scholar 

  25. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883–91.

    Article  CAS  Google Scholar 

  26. Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369(22):2093–104.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Division of Cardiology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA

    Vladimir Kaplinskiy & Eli V. Gelfand

Authors
  1. Vladimir Kaplinskiy
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Eli V. Gelfand
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Vladimir Kaplinskiy .

Editor information

Editors and Affiliations

  1. Department of Medicine, Division of Cardiology, Emory University School of Medicine, Atlanta, GA, USA

    Ankit A. Bhargava

  2. Department of Medicine, Division of Cardiology, Emory University School of Medicine, Atlanta, GA, USA

    Bryan J. Wells

  3. Department of Medicine, Division of Cardiology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA

    Pablo A. Quintero

Rights and permissions

Reprints and permissions

Copyright information

© 2022 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Kaplinskiy, V., Gelfand, E.V. (2022). Management of Atrial Fibrillation in the Outpatient Setting. In: Bhargava, A.A., Wells, B.J., Quintero, P.A. (eds) Handbook of Outpatient Cardiology . Springer, Cham. https://doi.org/10.1007/978-3-030-88953-1_23

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-88953-1_23

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-88952-4

  • Online ISBN: 978-3-030-88953-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation